{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:23:29Z","timestamp":1790490209066,"version":"4.1.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T00:00:00Z","timestamp":1571788800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Australian National Health and Medical Research Council","award":["GNT1107812"],"award-info":[{"award-number":["GNT1107812"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Clostridioides difficile (previously Clostridium difficile) is the leading cause of nosocomial, antibiotic-associated diarrhoea worldwide. Currently, the gold standard of treatment for C. difficile infection (CDI) is vancomycin or metronidazole, although these antibiotics also perturb the protective resident microbiota, often resulting in disease relapse. Thus, an urgent need remains for the development of new treatment strategies. Auranofin is an FDA-approved oral antirheumatic drug that was previously shown to inhibit C. difficile vegetative cell growth, toxin production and spore production in vitro.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To determine the efficacy of auranofin as a CDI therapeutic by examining the effect of treatment on toxin and spore production in vitro and in vivo, and on disease outcomes in mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>C. difficile cultures were treated with auranofin and examined for effects on sporulation and toxin production by sporulation assay and ELISA, respectively. Mice were pretreated with auranofin prior to infection with C. difficile and monitored for physiological conditions, survival and gut damage compared with control animals. Faeces from mice were analysed to determine whether auranofin reduces sporulation and toxin production in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Auranofin significantly reduces sporulation and toxin production under in vitro conditions and in infected mice in vivo. Mice treated with auranofin lost less weight, displayed a significant increase in survival rates and had significantly less toxin-mediated damage in their colon and caecum compared with control mice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Auranofin shows promise as a prospective therapeutic option for C. difficile infections.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkz430","type":"journal-article","created":{"date-parts":[[2019,10,9]],"date-time":"2019-10-09T07:53:05Z","timestamp":1570607585000},"source":"Crossref","is-referenced-by-count":15,"title":["Repurposing auranofin as a Clostridioides difficile therapeutic"],"prefix":"10.1093","author":[{"given":"Melanie L","family":"Hutton","sequence":"first","affiliation":[{"name":"Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Havva","family":"Pehlivanoglu","sequence":"additional","affiliation":[{"name":"Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Callum J","family":"Vidor","sequence":"additional","affiliation":[{"name":"Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan L","family":"James","sequence":"additional","affiliation":[{"name":"Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie J","family":"Thomson","sequence":"additional","affiliation":[{"name":"School of Medicine, Deakin University, Pigdons Road, Waurn Ponds, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dena","family":"Lyras","sequence":"additional","affiliation":[{"name":"Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,10,23]]},"reference":[{"key":"2019102309391702200_dkz430-B1","doi-asserted-by":"crossref","first-page":"447.","DOI":"10.1186\/s12879-016-1786-6","article-title":"Cost of hospital management of Clostridium difficile infection in United States\u2014a meta-analysis and modelling study","volume":"16","author":"Zhang","year":"2016","journal-title":"BMC Infect Dis"},{"key":"2019102309391702200_dkz430-B2","doi-asserted-by":"crossref","first-page":"16020.","DOI":"10.1038\/nrdp.2016.20","article-title":"Clostridium difficile infection","volume":"2","author":"Smits","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"2019102309391702200_dkz430-B3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.4161\/19490976.2014.969632","article-title":"Clostridium difficile virulence factors: insights into an anaerobic spore-forming pathogen","volume":"5","author":"Awad","year":"2014","journal-title":"Gut Microbes"},{"key":"2019102309391702200_dkz430-B4","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1038\/nature07822","article-title":"Toxin B is essential for virulence of Clostridium difficile","volume":"458","author":"Lyras","year":"2009","journal-title":"Nature"},{"key":"2019102309391702200_dkz430-B5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/nature09397","article-title":"The role of toxin A and toxin B in Clostridium difficile infection","volume":"467","author":"Kuehne","year":"2010","journal-title":"Nature"},{"key":"2019102309391702200_dkz430-B6","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/infdis\/jit426","article-title":"Importance of toxin A, toxin B, and CDT in virulence of an epidemic Clostridium difficile strain","volume":"209","author":"Kuehne","year":"2014","journal-title":"J Infect Dis"},{"key":"2019102309391702200_dkz430-B7","doi-asserted-by":"crossref","first-page":"e00551-15","DOI":"10.1128\/mBio.00551-15","article-title":"Defining the roles of TcdA and TcdB in localized gastrointestinal disease, systemic organ damage, and the host response during Clostridium difficile infections","volume":"6","author":"Carter","year":"2015","journal-title":"MBio"},{"key":"2019102309391702200_dkz430-B8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ijid.2006.04.003","article-title":"Toxin A-negative, toxin B-positive Clostridium difficile","volume":"11","author":"Drudy","year":"2007","journal-title":"Int J Infect Dis"},{"key":"2019102309391702200_dkz430-B9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2217\/fmb.14.115","article-title":"Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations","volume":"10","author":"King","year":"2015","journal-title":"Future Microbiol"},{"key":"2019102309391702200_dkz430-B10","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1155\/2015\/934594","article-title":"Fidaxomicin: a novel agent for the treatment of Clostridium difficile infection","volume":"26","author":"Zhanel","year":"2015","journal-title":"Can J Infect Dis Med Microbiol"},{"key":"2019102309391702200_dkz430-B11","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1056\/NEJMoa1602615","article-title":"Bezlotoxumab for prevention of recurrent Clostridium difficile infection","volume":"376","author":"Wilcox","year":"2017","journal-title":"N Engl J Med"},{"key":"2019102309391702200_dkz430-B12","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cgh.2011.08.014","article-title":"Treating Clostridium difficile infection with fecal microbiota transplantation","volume":"9","author":"Bakken","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2019102309391702200_dkz430-B13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.anaerobe.2018.01.003","article-title":"Non-conventional antimicrobial and alternative therapies for the treatment of Clostridium difficile infection","volume":"49","author":"Roshan","year":"2018","journal-title":"Anaerobe"},{"key":"2019102309391702200_dkz430-B14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/19490976.2017.1286006","article-title":"Challenges in fecal donor selection and screening for fecal microbiota transplantation: a review","volume":"8","author":"Woodworth","year":"2017","journal-title":"Gut Microbes"},{"key":"2019102309391702200_dkz430-B15","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s40268-015-0083-y","article-title":"Auranofin: repurposing an old drug for a golden new age","volume":"15","author":"Roder","year":"2015","journal-title":"Drugs R D"},{"key":"2019102309391702200_dkz430-B16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/ard.35.3.251","article-title":"Auranofin. New oral gold compound for treatment of rheumatoid arthritis","volume":"35","author":"Finkelstein","year":"1976","journal-title":"Ann Rheum Dis"},{"key":"2019102309391702200_dkz430-B17","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1128\/AAC.01675-12","article-title":"A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia","volume":"57","author":"Tejman-Yarden","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2019102309391702200_dkz430-B18","doi-asserted-by":"crossref","first-page":"22571.","DOI":"10.1038\/srep22571","article-title":"Antibacterial activity and mechanism of action of auranofin against multi-drug resistant bacterial pathogens","volume":"6","author":"Thangamani","year":"2016","journal-title":"Sci Rep"},{"key":"2019102309391702200_dkz430-B19","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.febslet.2008.02.028","article-title":"New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications","volume":"582","author":"Sannella","year":"2008","journal-title":"FEBS Lett"},{"key":"2019102309391702200_dkz430-B20","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1073\/pnas.1504022112","article-title":"Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis","volume":"112","author":"Harbut","year":"2015","journal-title":"Proc Natl Acad Sci USA"},{"key":"2019102309391702200_dkz430-B21","doi-asserted-by":"crossref","first-page":"32.","DOI":"10.3390\/toxins9010032","article-title":"Auranofin inhibits the enzyme activity of Pasteurella multocida toxin PMT in human cells and protects cells from intoxication","volume":"9","author":"Carle","year":"2017","journal-title":"Toxins (Basel)"},{"key":"2019102309391702200_dkz430-B22","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.toxicon.2015.04.012","article-title":"Thioredoxin reductase inhibitor auranofin prevents membrane transport of diphtheria toxin into the cytosol and protects human cells from intoxication","volume":"116","author":"Schnell","year":"2016","journal-title":"Toxicon"},{"key":"2019102309391702200_dkz430-B23","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.febslet.2012.11.007","article-title":"The thioredoxin reductase\u2013thioredoxin system is involved in the entry of tetanus and botulinum neurotoxins in the cytosol of nerve terminals","volume":"587","author":"Pirazzini","year":"2013","journal-title":"FEBS Lett"},{"key":"2019102309391702200_dkz430-B24","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1016\/j.celrep.2014.08.017","article-title":"Thioredoxin and its reductase are present on synaptic vesicles, and their inhibition prevents the paralysis induced by botulinum neurotoxins","volume":"8","author":"Pirazzini","year":"2014","journal-title":"Cell Rep"},{"key":"2019102309391702200_dkz430-B25","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ijantimicag.2018.09.018","article-title":"Antibacterial and antivirulence activities of auranofin against Clostridium difficile","volume":"53","author":"AbdelKhalek","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2019102309391702200_dkz430-B26","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00775-009-0466-z","article-title":"Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au\u2013Se adduct","volume":"14","author":"Jackson-Rosario","year":"2009","journal-title":"J Biol Inorg Chem"},{"key":"2019102309391702200_dkz430-B27","doi-asserted-by":"crossref","first-page":"7290","DOI":"10.1128\/JB.00731-07","article-title":"Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator","volume":"189","author":"Carter","year":"2007","journal-title":"J Bacteriol"},{"key":"2019102309391702200_dkz430-B28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ijantimicag.2018.08.014","article-title":"Antibacterial activity of rhodomyrtone on Clostridium difficile vegetative cells and spores in vitro","volume":"52","author":"Srisuwan","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"2019102309391702200_dkz430-B29","doi-asserted-by":"crossref","first-page":"e1005758.","DOI":"10.1371\/journal.ppat.1005758","article-title":"CdtR regulates TcdA and TcdB production in Clostridium difficile","volume":"12","author":"Lyon","year":"2016","journal-title":"PLoS Pathog"},{"key":"2019102309391702200_dkz430-B30","doi-asserted-by":"crossref","first-page":"3665.","DOI":"10.1038\/s41598-017-03982-5","article-title":"Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative","volume":"7","author":"Hutton","year":"2017","journal-title":"Sci Rep"},{"key":"2019102309391702200_dkz430-B31","doi-asserted-by":"crossref","first-page":"20096","DOI":"10.1074\/jbc.273.32.20096","article-title":"Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds","volume":"273","author":"Gromer","year":"1998","journal-title":"J Biol Chem"},{"key":"2019102309391702200_dkz430-B32","first-page":"279","article-title":"Gold complexes in the treatment of rheumatoid arthritis","volume":"41","author":"Messori","year":"2004","journal-title":"Met Ions Biol Syst"},{"key":"2019102309391702200_dkz430-B33","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1093\/rheumatology\/36.5.560","article-title":"Auranofin","volume":"36","author":"Kean","year":"1997","journal-title":"Br J Rheumatol"},{"key":"2019102309391702200_dkz430-B34","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1046\/j.1432-1327.2000.01703.x","article-title":"Thioredoxin reductase as a pathophysiological factor and drug target","volume":"267","author":"Becker","year":"2000","journal-title":"Eur J Biochem"},{"key":"2019102309391702200_dkz430-B35","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1038\/nm.2758","article-title":"A high-throughput drug screen for Entamoeba histolytica identifies a new lead and target","volume":"18","author":"Debnath","year":"2012","journal-title":"Nat Med"},{"key":"2019102309391702200_dkz430-B36","doi-asserted-by":"crossref","first-page":"D222","DOI":"10.1093\/nar\/gku1221","article-title":"CDD: NCBI\u2019s conserved domain database","volume":"43","author":"Marchler-Bauer","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2019102309391702200_dkz430-B37","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1093\/jac\/dkv163","article-title":"Auranofin efficacy against MDR Streptococcus pneumoniae and Staphylococcus aureus infections","volume":"70","author":"Aguinagalde","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2019102309391702200_dkz430-B38","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1007\/s10534-014-9743-6","article-title":"Drug repositioning: auranofin as a prospective antimicrobial agent for the treatment of severe staphylococcal infections","volume":"27","author":"Cassetta","year":"2014","journal-title":"Biometals"},{"key":"2019102309391702200_dkz430-B39","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jinorgbio.2014.05.008","article-title":"Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains","volume":"138","author":"Hokai","year":"2014","journal-title":"J Inorg Biochem"},{"key":"2019102309391702200_dkz430-B40","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1007\/s00018-005-5143-y","article-title":"Human selenoproteins at a glance","volume":"62","author":"Gromer","year":"2005","journal-title":"Cell Mol Life Sci"},{"key":"2019102309391702200_dkz430-B41","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/bjp.2008.161","article-title":"Arsenic trioxide and auranofin inhibit selenoprotein synthesis: implications for chemotherapy for acute promyelocytic leukaemia","volume":"154","author":"Talbot","year":"2008","journal-title":"Br J Pharmacol"},{"key":"2019102309391702200_dkz430-B42","doi-asserted-by":"crossref","first-page":"8487","DOI":"10.1128\/JB.01370-06","article-title":"Analysis of proline reduction in the nosocomial pathogen Clostridium difficile","volume":"188","author":"Jackson","year":"2006","journal-title":"J Bacteriol"},{"key":"2019102309391702200_dkz430-B43","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.resmic.2014.10.002","article-title":"Integration of metabolism and virulence in Clostridium difficile","volume":"166","author":"Bouillaut","year":"2015","journal-title":"Res Microbiol"},{"key":"2019102309391702200_dkz430-B44","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1128\/JB.01492-12","article-title":"Proline-dependent regulation of Clostridium difficile Stickland metabolism","volume":"195","author":"Bouillaut","year":"2013","journal-title":"J Bacteriol"},{"key":"2019102309391702200_dkz430-B45","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1099\/13500872-145-7-1683","article-title":"Suppression of toxin production in Clostridium difficile VPI 10463 by amino acids","volume":"145","author":"Karlsson","year":"1999","journal-title":"Microbiology"},{"key":"2019102309391702200_dkz430-B46","doi-asserted-by":"crossref","first-page":"14672.","DOI":"10.1038\/s41598-017-15236-5","article-title":"Using CRISPR\u2013Cas9-mediated genome editing to generate C. difficile mutants defective in selenoproteins synthesis","volume":"7","author":"McAllister","year":"2017","journal-title":"Sci Rep"},{"key":"2019102309391702200_dkz430-B47","first-page":"19","article-title":"Pharmacology of auranofin: overview and update","volume":"63","author":"Gottlieb","year":"1986","journal-title":"Scand J Rheumatol Suppl"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz430\/30267403\/dkz430.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/advance-article-pdf\/doi\/10.1093\/jac\/dkz430\/30267403\/dkz430.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T11:35:29Z","timestamp":1571830529000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/advance-article\/doi\/10.1093\/jac\/dkz430\/5603652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,23]]},"references-count":47,"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz430","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,23]]},"article-number":"dkz430"}}